Human Longevity Inc. Hires Life Sciences Leader, Mark Winham, As Chief Operating Officer

SAN DIEGO, Aug. 25, 2015 /PRNewswire/ -- Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that Mark A. Winham has joined the company as Chief Operating Officer. Winham, who brings more than 25 years of life sciences, medical operations and technical experience, will report directly to HLI's CEO, J. Craig Venter, Ph.D.

In this new role as COO, Winham will be responsible for managing all HLI sequencing, laboratory and product pipeline operations as well as all facility operations. HLI currently has three locations in San Diego and Mountain View, California and Singapore.

Winham comes to HLI most recently from Millennium Health, where he was COO and was primarily responsible for strategic planning, development of Laboratory Operations and R&D activities.

Prior to his role at Millennium Health, Mark spent 10 years at Life Technologies, where he held a series of significant positions including Vice President of Global Manufacturing. There he was responsible for a manufacturing organization with more than 40 sites world-wide having approximately 2,500 employees and developing products and services totalling $2.9 billion in revenue. Winham was VP of Global Manufacturing with Applied Biosystems when the company was acquired by Life Technologies.

Winham's early career was shaped at Sanofi Aventis, Johnson and Johnson and Advanced Medical Solutions.

"Mark brings substantial operational vision and technical leadership to HLI. He will play a critical role in helping to manage the growth and complexities of our business as we expand our operations globally," said Dr. J. Craig Venter, Co-Founder and CEO of Human Longevity, Inc.

Winham holds a Bachelor of Sciences degree from Napier University in Edinburgh, Scotland.

About Human Longevity, Inc.
Human Longevity, Inc. (HLI) is the genomics-based, technology-driven company creating the world's largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine. A privately held company headquartered in San Diego, CA, HLI was founded in 2013 by pioneers in the fields of genomics and stem cell therapy. HLI will be licensing access to its database, and developing new diagnostics and therapeutics as part of their product offerings. For more information please visit,

Logo -

To view the original version on PR Newswire, visit:

SOURCE Human Longevity, Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.